259 related articles for article (PubMed ID: 30514160)
41. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
[TBL] [Abstract][Full Text] [Related]
42. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of tumor cell proliferation in human uterine leiomyomas by vitamin D via Wnt/β-catenin pathway.
Corachán A; Ferrero H; Aguilar A; Garcia N; Monleon J; Faus A; Cervelló I; Pellicer A
Fertil Steril; 2019 Feb; 111(2):397-407. PubMed ID: 30458994
[TBL] [Abstract][Full Text] [Related]
44. Absence of predictable long-term molecular effect of ulipristal acetate (UPA) on the endometrium.
Kolanska K; Varinot J; Canlorbe G; Bergeron C; Mekinian A; Capmas P; Koskas M; Daraï E; Aractingi S; Bendifallah S; Chabbert-Buffet N
Reprod Biomed Online; 2019 May; 38(5):825-834. PubMed ID: 30898512
[TBL] [Abstract][Full Text] [Related]
45. Repeated-intermittent use of ulipristal acetate for the management of uterine fibroids: an Italian pharmacoeconomic evaluation.
Maratea D
Minerva Ginecol; 2016 Feb; 68(1):15-20. PubMed ID: 26990098
[TBL] [Abstract][Full Text] [Related]
46. Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
[TBL] [Abstract][Full Text] [Related]
47. Phase III long-term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids.
Osuga Y; Nakano Y; Yamauchi Y; Murakawa H
J Obstet Gynaecol Res; 2021 Sep; 47(9):3269-3278. PubMed ID: 34109697
[TBL] [Abstract][Full Text] [Related]
48. Spontaneous Pregnancy Following Ulipristal Acetate Treatment in a Woman with a Symptomatic Uterine Fibroid.
Murad K
J Obstet Gynaecol Can; 2016 Jan; 38(1):75-9. PubMed ID: 26872760
[TBL] [Abstract][Full Text] [Related]
49. Vitamin D and Uterine Fibroids-Review of the Literature and Novel Concepts.
Ciebiera M; Włodarczyk M; Ciebiera M; Zaręba K; Łukaszuk K; Jakiel G
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011902
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.
Donnez J; Hudecek R; Donnez O; Matule D; Arhendt HJ; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Terrill P; Osterloh I; Loumaye E
Fertil Steril; 2015 Feb; 103(2):519-27.e3. PubMed ID: 25542821
[TBL] [Abstract][Full Text] [Related]
51. Fibroid management in premenopausal women.
Donnez J; Courtoy GE; Dolmans MM
Climacteric; 2019 Feb; 22(1):27-33. PubMed ID: 30601065
[TBL] [Abstract][Full Text] [Related]
52. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
53. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review.
Donnez J; Courtoy GE; Donnez O; Dolmans MM
Reprod Biomed Online; 2018 Aug; 37(2):216-223. PubMed ID: 29706284
[TBL] [Abstract][Full Text] [Related]
54. Long-term vitamin D treatment decreases human uterine leiomyoma size in a xenograft animal model.
Corachán A; Ferrero H; Escrig J; Monleon J; Faus A; Cervelló I; Pellicer A
Fertil Steril; 2020 Jan; 113(1):205-216.e4. PubMed ID: 31739978
[TBL] [Abstract][Full Text] [Related]
55. Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.
Liu JH; Soper D; Lukes A; Gee P; Kimble T; Kroll R; Mallick M; Chan A; Gillard P; Harrington A; Sniukiene V; Shulman LP
Obstet Gynecol; 2018 Nov; 132(5):1241-1251. PubMed ID: 30303900
[TBL] [Abstract][Full Text] [Related]
56. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids.
Luyckx M; Squifflet JL; Jadoul P; Votino R; Dolmans MM; Donnez J
Fertil Steril; 2014 Nov; 102(5):1404-9. PubMed ID: 25241376
[TBL] [Abstract][Full Text] [Related]
57. Steroid hormones and hormone antagonists regulate the neural marker neurotrimin in uterine leiomyoma.
Parikh TP; Malik M; Britten J; Aly JM; Pilgrim J; Catherino WH
Fertil Steril; 2020 Jan; 113(1):176-186. PubMed ID: 32033718
[TBL] [Abstract][Full Text] [Related]
58. Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy.
Brun JL; Rajaonarison J; Froeliger A; Monseau-Thiburce AC; Randriamboavonjy R; Vogler A
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():13-18. PubMed ID: 29328939
[TBL] [Abstract][Full Text] [Related]
59. Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study.
Giarrè G; Franchini M; Castellacci E; Malune ME; Di Spiezio Sardo A; Saccone G; Angioni S
Gynecol Endocrinol; 2020 Feb; 36(2):171-174. PubMed ID: 31392917
[TBL] [Abstract][Full Text] [Related]
60. Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids.
Halder SK; Sharan C; Al-Hendy O; Al-Hendy A
Reprod Sci; 2014 Sep; 21(9):1108-19. PubMed ID: 24925855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
